Monitor for selling by Sealbond once the S-3 becomes effective. The controlling stockholder's ability to sell a large block into a thin market ($42M cap) could pressure the stock. Watch for any prospectus supplement indicating actual sales.
Price Chart
Executive Summary
Dogwood Therapeutics filed an S-3 registration statement to register 4,098,360 shares for resale by its controlling stockholder Sealbond Limited. The shares were issued in a private placement that closed on October 26, 2026, at $1.22 per share, raising approximately $5.0 million for working capital. The company will not receive any proceeds from the resale, but the registration enables Sealbond to sell its stake into the public market, creating potential overhang.
Key Facts
- S-3 registers 4,098,360 shares for resale by Sealbond Limited, the controlling stockholder.
- Shares were issued in a private placement at $1.22 per share for gross proceeds of approximately $5.0 million.
- Sealbond beneficially owns 67.8% of outstanding common stock; together with affiliate Conjoint Inc., the group controls 75.2%.
- The company will not receive any proceeds from the resale.
- The filing follows two recent SC 13D/A filings (Oct 21 and Oct 27, 2026) detailing the same private placement.
- The auditor's report includes a going concern explanatory paragraph.
- Market cap is $42M; the registered shares represent about 10.7% of the 38.2M shares outstanding.
- The company has 8 offering/registration filings in the last 24 months, indicating repeated capital raises.
Financial Impact
Potential selling pressure from up to 4,098,360 shares (10.7% of outstanding) registered for resale by the controlling stockholder.
Risk Factors
- Resale of 4.1M shares by controlling stockholder could create significant overhang and downward price pressure.
- Going concern qualification in auditor's report signals financial distress.
- High frequency of capital raises (8 filings in 24 months) suggests ongoing cash needs.
- Concentrated ownership (75.2% by Sealbond/Conjoint) limits public float and liquidity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001104659-26-120650 |
| Document: tm2628568d1_ex-filingfees.htm | 0001104659-26-120650 |
| Document: tm2628568d1_ex5-1.htm | 0001104659-26-120650 |
| Document: tm2628568d1_ex23-1.htm | 0001104659-26-120650 |
| Document: 0001104659-26-120650-index-headers.html | 0001104659-26-120650 |
| Document: 0001104659-26-120650-index.html | 0001104659-26-120650 |
| Document: 0001104659-26-120650.txt | 0001104659-26-120650 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 30, 2026 2d ago | S-3 | $1.25 | awaiting T+60 | awaiting T+60 | $1.28 (−2.77%) |
Oct 27, 2026 5d ago | SC 13D/A | $1.24 | awaiting T+60 | awaiting T+60 | $1.28 (+3.23%) |
Oct 21, 2026 11d ago | SC 13D/A | $1.12 | awaiting T+60 | awaiting T+60 | $1.28 (+14.29%) |
Oct 19, 2026 13d ago | 8-K | $1.21 | awaiting T+60 | awaiting T+60 | $1.28 (+5.79%) |
Oct 19, 2026 13d ago | Press Release | $1.21 | awaiting T+60 | awaiting T+60 | $1.28 (+5.79%) |
Aug 13, 2026 11w ago | 8-K | $1.98 | awaiting T+60 | awaiting T+60 | $1.28 (+35.35%) |
May 18, 2026 23w ago | Press Release | $1.70 $1.93 | ▲ +13.24% | ▲ +8.38% | $1.28 (−24.71%) |
May 14, 2026 24w ago | 8-K | No price | awaiting T+60 | awaiting T+60 | No price |
May 14, 2026 24w ago | Press Release | $1.98 $1.83 | ▼ −7.58% | ▼ −11.16% | $1.28 (−35.35%) |
Apr 15, 2026 28w ago | Press Release | $1.71 $1.42 | ▼ −16.96% | ▼ −25.10% | $1.28 (−25.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers